140 filings
Page 2 of 7
8-K
1m9gflr
8 Jun 22
Departure of Directors or Certain Officers
4:06pm
8-K
7h5hg6x84xnyrgpq5kt
9 May 22
FibroGen Reports First Quarter 2022 Financial Results
4:09pm
8-K
skzcft57n
28 Feb 22
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
4:06pm
8-K
suo9svn9
9 Nov 21
FibroGen Reports Third Quarter 2021 Financial Results
4:06pm
8-K
sbxhzpjppq398
27 Aug 21
Departure of Directors or Certain Officers
4:31pm
8-K
wf5jm
20 Aug 21
Other Events
12:00am
8-K
jqzl9qrojkwt2h6
16 Aug 21
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
5:23pm
8-K
chpzh5uus0 ag1uwh
11 Aug 21
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
8:30am
8-K
o27fqtif8pgal18y d2
9 Aug 21
FibroGen Reports Second Quarter 2021 Financial Results
4:05pm
8-K
qz10mr7topq7llwu27zd
20 Jul 21
Entry into a Material Definitive Agreement
4:05pm
8-K
80368rpq3t 308podfb0
25 Jun 21
Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
5:26pm
8-K
fvm6y67hj5
17 Jun 21
FibroGen and HiFiBiO Announce Transformative Partnership to
4:16pm
8-K
41krn
7 Jun 21
Entry into a Material Definitive Agreement
4:32pm
8-K
c384 5fuef76qfsh
27 May 21
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
rq4a6u7mznvs vr6w
14 May 21
Regulation FD Disclosure
5:22pm
8-K
xhuutcvh6lewy5
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
ez16af7d5fv3szr2 mo
13 Apr 21
Departure of Directors or Certain Officers
4:22pm
8-K
xor k2vgg3lwt8bi
7 Apr 21
Regulation FD Disclosure
8:30am
8-K
2qud14ursi2b
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
4:59pm
8-K
5qoi5
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm